Monoclonal antibodies and side-effect management

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are a growing class of targeted cancer therapies.
• Eight mAbs are FDA-approved for cancer treatment in the U.S.
• Oncology nurses require comprehensive knowledge of these agents.

Purpose of the Study:

• To provide oncology nurses with essential information on monoclonal antibodies.
• To outline mechanisms of action, indications, and administration guidelines.
• To support effective patient and family education regarding mAb therapy.

Main Methods:

• Review of current literature and FDA-approved monoclonal antibodies for cancer.
• Synthesis of information on mAb mechanisms, clinical uses, and adverse events.
• Outline of best practices for infusion and symptom management.

Main Results:

• Monoclonal antibodies represent a significant advancement in cancer treatment.
• Understanding specific and overlapping side effects is crucial for patient safety.
• Nurses play a vital role in managing side effects and educating patients.

Conclusions:

• Oncology nurses must be proficient in managing monoclonal antibody therapy.
• This article serves as a resource for understanding mAb indications, administration, and side effects.
• Effective management and education enhance patient outcomes in cancer care.